More than 35 industry players claim to offer services for the identification, characterization and d

Drug discovery is challenging and involves several complexities. In order to continue to add new molecules their pipelines, drug developers are opting to outsource such operations to contract research organizations (CROs). Outsourcing of peptides and macrocycle drug discovery has emerged as one of the recent trends in the overall pharmaceutical domain.

To order this 180+ page report, which features 90+ figures and 85+ tables, please visit this –

The USD 1.5 billion (by 2030) financial opportunity within the peptides and macrocycles drug discovery service and platform providers market has been analyzed across the following segments:
 Type of peptides
 Synthetic peptides
 Biologic and recombinant peptides

 Type of discovery steps
 Target identification and validation
 Hit identification
 Lead generation
 Lead optimization

 Therapeutic Area
 Oncological disorders
 Metabolic disorders
 Cardiovascular disorders
 Infectious diseases
 Urological disorders
 Endocrine disorders
 CNS disorders
 Other diseases

 Company Size
 Small companies
 Mid-sized companies
 Large and very large companies

 Key geographical regions
 Europe
 North America
 Asia-Pacific and the Rest of the World

The report features inputs from eminent industry stakeholders, according to whom peptide and macrocycles drug discovery outsourcing market is continuously pacing up. The report includes detailed transcripts of discussions held with the following experts:
 Mark I Peterson (CEO, Cyclenium Pharma)
 Jan Hoflack (Chief Scientific Officer, Head of Biotech Business Unit, Oncodesign)
The research covers profiles of key players that offer peptides and macrocyclic drugs discovery .

Contact Details

Gaurav Chaudhary

+1 (415) 800 3415  

Leave a Reply

Your email address will not be published. Required fields are marked *